Clinical Trial

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed, refractory metastatic GCT.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-14; most recent amendment 2025-11-19.
Status change: Not Yet Recruiting → Recruiting 2025-11-04
Trial Details
NCT Number NCT06937866
Lead Sponsor Indiana University
Collaborators: Exelixis
Conditions Germ Cell Tumor
Enrollment 38 participants
Start Date 2025-11-12
Primary Completion 2030-03 (estimated)
Study Completion 2031-09 (estimated)
Updated on ClinicalTrials.gov 2025-11-21